RT Journal Article
SR Electronic
T1 Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 434
OP 441
DO 10.2967/jnumed.117.202945
VO 59
IS 3
A1 Jeremie Calais
A1 Wolfgang P. Fendler
A1 Matthias Eiber
A1 Jeannine Gartmann
A1 Fang-I Chu
A1 Nicholas G. Nickols
A1 Robert E. Reiter
A1 Matthew B. Rettig
A1 Leonard S. Marks
A1 Thomas E. Ahlering
A1 Linda M. Huynh
A1 Roger Slavik
A1 Pawan Gupta
A1 Andrew Quon
A1 Martin S. Allen-Auerbach
A1 Johannes Czernin
A1 Ken Herrmann
YR 2018
UL http://jnm.snmjournals.org/content/59/3/434.abstract
AB In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05–202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3–6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes.